Assessment of Tumor Markers in Cerebrospinal Fluid

Cerebrospinal fluid cytology in patients with cancer

“…The interval between samples was 1 -6 days (mean, 3.9 days). In 24 of the 27 Error Based on Sampling from a Suboptimal Site patients (89%), the CSF cytology was positive on the Of the 24 patients contributing CSF to this study, 13 first tap. Of those 24 initially positive patients, 9 were had clinical or radiographic evidence of cranial (corticytologically negative (i.e., only 15 of 24 were positive) cal or brainstem) leptomeningeal disease, 6 had spinal on the second tap, giving a false-negative rate of 38% disease, and 5 had symptoms or radiographic signs (95% CI, 19 -59%).…”

Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors

“…The tumor markers in cerebrospinal fluid (CSF) [1,2] include beta-glucuronidase, polyamines (putrescine, spermidine, spermine), and carcinoembryonic antigen (CEA). The increase in beta-glucuronidase is specific to meningeal carcinomatosis [3][4][5].…”

Laboratory processing of cerebrospinal fluid specimens

“…Assisting the clinician in obtaining proper specimen-packaging materials and courier services will also maximize cooperation in this area. Lastly, available evidence supports the following conclusions: ( 1 ) the larger the volume of CSF submitted, the more likely an abnormal CSF will yield positive microbiological and/or cytological diagnoses; andl (2) the incidence of post-LP headache in patients is not significantly increased by the volume of CSF removed, at least within the range of [20][21][22][23][24][25][26][27][28][29][30] Future Trends lndications for CSF study continue to evolve as progress is made in diagnostic and treatment techniques. Rapid advances in neuroradiologic imaging techniques have made CSF examination an unnecessary, or even inappropriate, screening test in some clinical settings (by demonstrating, for example, an impending herniation syndrome secondary to a mass lesion).…”

“…Attempts are in progress to apply monoclonal antibody panels to CSF, for example, in order to aid the differential diagnosis of neoplasm^,'*^^^ and recent reviews of this subject are available. 20,21 Flow Cytometry Application of this technique to CSF, as presently utilized, poses some logistical problems, which primarily relate to the cellularity of the specimen. 22 For example, immunofluorescent cell markers may be satisfactorily studied on as few as 100 cells, but a more reliable result is more likely with 1,000 or more cells.…”